Cover Image

Where does allogeneic stem cell transplantation fit in the treatment of chronic lymphocytic leukemia?

Allogeneic hematopoietic stem cell transplantation (alloHSCT) has been considered as the treatment of choice for patients with high-risk chronic lymphocytic leukemia (CLL) (i.e., refractory to purine analogs, short response (<24 months) to intensive treatments, and/or presence of 17p/TP53 abnorma...

Full description

Saved in:
Bibliographic Details
Main Authors: Dreger, Peter (Author) , Montserrat, Emili (Author)
Format: Article (Journal)
Language:English
Published: 5 February 2015
In: Current hematologic malignancy reports
Year: 2015, Volume: 10, Issue: 1, Pages: 59-64
ISSN:1558-822X
DOI:10.1007/s11899-014-0242-1
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1007/s11899-014-0242-1
Get full text
Author Notes:Peter Dreger, Emili Montserrat, on behalf of the European Society for Blood and Marrow Transplantation (EBMT) and the European Research Initiative on CLL (ERIC)

MARC

LEADER 00000caa a2200000 c 4500
001 1702836983
003 DE-627
005 20240406193221.0
007 cr uuu---uuuuu
008 200629s2015 xx |||||o 00| ||eng c
024 7 |a 10.1007/s11899-014-0242-1  |2 doi 
035 |a (DE-627)1702836983 
035 |a (DE-599)KXP1702836983 
035 |a (OCoLC)1341341923 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 33  |2 sdnb 
100 1 |a Dreger, Peter  |e VerfasserIn  |0 (DE-588)1028891881  |0 (DE-627)732699894  |0 (DE-576)376320966  |4 aut 
245 1 0 |a Where does allogeneic stem cell transplantation fit in the treatment of chronic lymphocytic leukemia?  |c Peter Dreger, Emili Montserrat, on behalf of the European Society for Blood and Marrow Transplantation (EBMT) and the European Research Initiative on CLL (ERIC) 
264 1 |c 5 February 2015 
300 |a 6 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Gesehen am 29.06.2020 
520 |a Allogeneic hematopoietic stem cell transplantation (alloHSCT) has been considered as the treatment of choice for patients with high-risk chronic lymphocytic leukemia (CLL) (i.e., refractory to purine analogs, short response (<24 months) to intensive treatments, and/or presence of 17p/TP53 abnormalities). Currently, new and highly effective therapeutic agents targeting BCR-mediated intracellular signal transduction have been incorporated into the CLL treatment armamentarium. These signal transduction inhibitors (STI) will change the algorithms of high-risk CLL (HR-CLL) management. Despite the limited body of evidence, there is sufficient rationale for withholding alloHSCT in patients with 17p-/TP53mut CLL in first remission. In contrast, the perspectives of patients with relapsed 17p-/TP53mut CLL remain uncertain even if responding to STI. The same accounts for patients with HR-CLL progressing under STI. In both scenarios, it is reasonable to consider alloHSCT, ideally after response to alternative STI regimens. 
700 1 |a Montserrat, Emili  |e VerfasserIn  |0 (DE-588)1209068869  |0 (DE-627)1696145554  |4 aut 
710 2 |a European Group for Blood and Marrow Transplantation  |e AuftraggeberIn  |0 (DE-588)5130460-0  |0 (DE-627)188682082  |0 (DE-576)195258746  |4 pat 
773 0 8 |i Enthalten in  |t Current hematologic malignancy reports  |d Philadelphia, Pa. : Current Science, 2006  |g 10(2015), 1, Seite 59-64  |h Online-Ressource  |w (DE-627)534675549  |w (DE-600)2374151-X  |w (DE-576)306834618  |x 1558-822X  |7 nnas  |a Where does allogeneic stem cell transplantation fit in the treatment of chronic lymphocytic leukemia? 
773 1 8 |g volume:10  |g year:2015  |g number:1  |g pages:59-64  |g extent:6  |a Where does allogeneic stem cell transplantation fit in the treatment of chronic lymphocytic leukemia? 
856 4 0 |u https://doi.org/10.1007/s11899-014-0242-1  |x Verlag  |x Resolving-System  |z lizenzpflichtig  |3 Volltext 
951 |a AR 
992 |a 20200629 
993 |a Article 
994 |a 2015 
998 |g 1028891881  |a Dreger, Peter  |m 1028891881:Dreger, Peter  |d 910000  |d 910100  |e 910000PD1028891881  |e 910100PD1028891881  |k 0/910000/  |k 1/910000/910100/  |p 1  |x j 
999 |a KXP-PPN1702836983  |e 3692035276 
BIB |a Y 
SER |a journal 
JSO |a {"language":["eng"],"title":[{"title":"Where does allogeneic stem cell transplantation fit in the treatment of chronic lymphocytic leukemia?","title_sort":"Where does allogeneic stem cell transplantation fit in the treatment of chronic lymphocytic leukemia?"}],"type":{"media":"Online-Ressource","bibl":"article-journal"},"recId":"1702836983","origin":[{"dateIssuedKey":"2015","dateIssuedDisp":"5 February 2015"}],"relHost":[{"language":["eng"],"part":{"issue":"1","pages":"59-64","extent":"6","text":"10(2015), 1, Seite 59-64","year":"2015","volume":"10"},"title":[{"title_sort":"Current hematologic malignancy reports","title":"Current hematologic malignancy reports"}],"pubHistory":["1.2006 -"],"note":["Gesehen am 27.02.14"],"id":{"eki":["534675549"],"zdb":["2374151-X"],"issn":["1558-822X"]},"disp":"Where does allogeneic stem cell transplantation fit in the treatment of chronic lymphocytic leukemia?Current hematologic malignancy reports","physDesc":[{"extent":"Online-Ressource"}],"recId":"534675549","origin":[{"dateIssuedKey":"2006","publisher":"Current Science","dateIssuedDisp":"2006-","publisherPlace":"Philadelphia, Pa."}],"type":{"bibl":"periodical","media":"Online-Ressource"}}],"note":["Gesehen am 29.06.2020"],"corporate":[{"display":"European Group for Blood and Marrow Transplantation","role":"pat"}],"id":{"doi":["10.1007/s11899-014-0242-1"],"eki":["1702836983"]},"physDesc":[{"extent":"6 S."}],"name":{"displayForm":["Peter Dreger, Emili Montserrat, on behalf of the European Society for Blood and Marrow Transplantation (EBMT) and the European Research Initiative on CLL (ERIC)"]},"person":[{"family":"Dreger","role":"aut","given":"Peter","display":"Dreger, Peter"},{"display":"Montserrat, Emili","given":"Emili","role":"aut","family":"Montserrat"}]} 
SRT |a DREGERPETEWHEREDOESA5201 

Similar Items